Literature DB >> 12786613

Review article: management of mild and severe gastro-oesophageal reflux disease.

G N J Tytgat1.   

Abstract

Treatment of endosocopy-negative gastro-oesophageal reflux disease (s-GERD) should be directed towards rapid relief of symptoms and then maintenance of relief using minimum yet effective therapy. Responses to proton pump inhibitors are somewhat lower in s-GERD patients compared to GERD with overt erosive damage (e-GERD). The reasons for a lower response rate are not clear but may relate to the inclusion of patients who do not have reflux disease or patients with a lower oesophageal sensory threshold. Also poorly understood is the lower yield of complete heartburn relief when the number of associated dyspeptic symptoms is high. Some form of long-term therapy is needed in the majority of patients. 'On demand' proton pump inhibitor therapy to control reflux symptoms is a new and attractive option. Time to study discontinuation due to insufficient control of heartburn, or any other reason resulting in unwillingness to continue with on-demand therapy, is a pragmatic outcome that is well suited to definition of the efficacy of on-demand therapy. The goals of treatment of e-GERD should be to relieve symptoms and to heal lesions. Symptom severity and much less endoscopic abnormalities drives the therapeutic choices. When symptoms are mild or intermittent and when oesophagitis is of limited degree, standard dose proton pump inhibitor is usually instituted. Fewer and fewer clinicians would still opt for an H2-receptor antagonist. If there is moderate or severe oesophagitis or if symptoms are particularly troublesome, then the patient should start with standard-dose proton pump inhibitor therapy once a day, but not uncommonly a b.d. dosage maybe necessary. Once the dose of the acid suppressant that relieves symptoms is found, this dose should be maintained for a period of 3 months. After this time, an attempt should be made to reduce the dose. If symptoms recur, then the patients should go back to the full-dose proton pump inhibitor and a plan should be formulated for long-term treatment. The long-term treatment options vary between ongoing acid and suppressant therapy, with occasional attempts to reduce the dose, or to go for 'on demand' therapy and (rarely) includes consideration for surgery or endoscopic anti-reflux therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12786613     DOI: 10.1046/j.1365-2036.17.s2.5.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease.

Authors:  K Størdal; G B Johannesdottir; B S Bentsen; P K Knudsen; K C L Carlsen; O Closs; M Handeland; H K Holm; L Sandvik
Journal:  Arch Dis Child       Date:  2005-09       Impact factor: 3.791

2.  Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis.

Authors:  Jing Sun; Yao-Zong Yuan; Xiao-Hua Hou; Duo-Wu Zou; Bin Lu; Min-Hu Chen; Fei Liu; Kai-Chun Wu; Xiao-Ping Zou; Yan-Qing Li; Li-Ya Zhou
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

3.  Prevalence of acid reflux in functional dyspepsia and its association with symptom profile.

Authors:  J Tack; P Caenepeel; J Arts; K-J Lee; D Sifrim; J Janssens
Journal:  Gut       Date:  2005-06-21       Impact factor: 23.059

4.  Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.

Authors:  Hung-Hsien Chiang; Deng-Chyang Wu; Pin-I Hsu; Chao-Hung Kuo; Wei-Chen Tai; Shih-Cheng Yang; Keng-Liang Wu; Chih-Chien Yao; Cheng-En Tsai; Chih-Ming Liang; Yao-Kuang Wang; Jiunn-Wei Wang; Chih-Fang Huang; Seng-Kee Chuah
Journal:  Drug Des Devel Ther       Date:  2019-04-26       Impact factor: 4.162

5.  The daily response for proton pump inhibitor treatment in Japanese reflux esophagitis and non-erosive reflux disease.

Authors:  Hiroshi Shida; Yuzo Sakai; Hiroyuki Hamada; Tetsuo Takayama
Journal:  J Clin Biochem Nutr       Date:  2012-11-13       Impact factor: 3.114

6.  Responsiveness of measures of heartburn improvement in non-erosive reflux disease.

Authors:  Ola Junghard; Katarina Halling
Journal:  Health Qual Life Outcomes       Date:  2007-06-11       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.